Charlie Karasek

This inventor holds 25 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Antibody Therapeutics. Top assignees: H. Lundbeck A/s, Alder Biopharmaceuticals, Inc., University of Iowa Research Foundation. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charlie Karasek. Retrieved from https://idiyas.com/inventor/charlie-karasek

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 2 (Patent Applications = 8)

Average Co-Inventor Count = 15.0

ph-index = 2

Forward Citations = 32(Granted Patents)

Company Filing History:

Alder Biopharmaceuticals, Inc.

patents

3 out of 925

University of Iowa Research Foundation

patents

4. 2 out of 98

Alderbio Holdings LLC

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Anti-PACAP Antibodies

Humanized Antibodies

PACAP-Associated Conditions

Migraine Treatment

Photophobia

Nucleic Acids

Antibody Fragments

Headache Relief

Therapeutic Uses

Screening Methods

Inhibition Techniques

Humanized Anti-ACTH

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747291 - NUCLEIC ACIDS ENCODING HUMANIZED ANTI-PACAP ANTIBODIES (2026-09-29),

2. 12545725 - Anti-PACAP antibodies, nucleic acids and methods of making thereof (2026-02-10),

3. 12428475 - Humanized anti-ACTH antibodies and use thereof (2025-09-30),

4. 12351627 - Anti-ACTH antibodies and use thereof (2025-07-08),

5. 12162936 - Methods of treatment with anti-PACAP antibodies (2024-12-10),

6. 12077581 - Anti-PACAP antibodies and uses thereof (2024-09-03),

7. 11993648 - Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion (2024-05-28),

8. 11938185 - Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies (2024-03-26),

9. 11427631 - Anti-ACTH antibodies and use thereof (2022-08-30),

10. 11352409 - Anti-PACAP antibodies and uses thereof (2022-06-07),

11. 11254741 - Anti-PACAP antibodies (2022-02-22),

12. 11117960 - Humanized anti-ACTH antibodies and use thereof (2021-09-14),

13. 10981985 - Anti-PACAP antibodies (2021-04-20),

14. 10981984 - Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion (2021-04-20),

15. 10975135 - Humanized anti-PACAP antibodies (2021-04-13),

Title: The Innovative Mind of Charlie Karasek: Pioneering Anti-PACAP Antibodies

Introduction

Charlie Karasek, an accomplished inventor based in Seattle, WA, has made significant contributions to the field of biomedical innovation. With an impressive portfolio of 21 patents, he focuses on developing methods and treatments that leverage antibodies to address various medical conditions. His recent work centers around the use of antagonistic antibodies that target PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide), a molecule implicated in numerous physiological processes.

Latest Patents

Among his latest patents, Karasek has developed advanced methods of treatment utilizing anti-PACAP antibodies. These innovative antibodies are designed to inhibit, block, or neutralize biological effects associated with PACAP, such as vasodilation. The patents detail how these antibodies may include specific polypeptides with particular binding capabilities, enabling them to compete for binding sites on human PACAP. Furthermore, his inventions aim to utilize these antibodies for diagnosing and treating disorders tied to PACAP activity, making significant strides in the realms of headache and migraine therapies.

Career Highlights

Throughout his career, Charlie Karasek has worked with notable companies in the pharmaceutical industry, including H. Lundbeck A/S and Alder Biopharmaceuticals, Inc. His work at these organizations has allowed him to refine his expertise and contribute to the development of advanced therapeutic solutions for challenging medical conditions.

Collaborations

In his journey as an inventor, Karasek has collaborated with esteemed colleagues, including Benjamin H. Dutzar and Daniel S. Allison. These collaborations have likely enhanced the innovative process, allowing for a diverse exchange of ideas and expertise, which is essential in the rapidly evolving field of biopharmaceutical research.

Conclusion

Charlie Karasek's work exemplifies a commitment to innovation in the biomedical sector. His patents related to anti-PACAP antibodies signify not only a strong understanding of complex medical challenges but also an impactful approach to treatment that may benefit many individuals suffering from related disorders. With a solid foundation of experience and collaboration, Karasek continues to be a key player in the pursuit of medical advancements.

Profile summary based on public USPTO records.